Sign In
Buy INBX
$95.22
+1.59 (+1.70%)
At Close: Jun 03, 2026
Inhibrx Reports Second Quarter 2025 Financial Results
04:05pm, Wednesday, 13'th Aug 2025
SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completi
Inhibrx Reports First Quarter 2025 Financial Results
04:05pm, Wednesday, 14'th May 2025
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
04:05pm, Tuesday, 01'st Apr 2025
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage developm
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
04:05pm, Monday, 17'th Mar 2025
SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncol
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
04:15pm, Monday, 13'th Jan 2025
SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announc
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
04:24pm, Thursday, 14'th Nov 2024
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following t
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
11:45am, Tuesday, 05'th Nov 2024
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing p
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
04:00pm, Monday, 04'th Nov 2024
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong em
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
06:54pm, Tuesday, 13'th Aug 2024
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials an
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
02:42pm, Friday, 07'th Jun 2024
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeu
Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)
07:46am, Wednesday, 05'th Jun 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
04:00pm, Friday, 24'th May 2024
SAN DIEGO , May 24, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
06:36pm, Friday, 10'th May 2024
SAN DIEGO , May 10, 2024 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the Company of 92%
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inhibrx, Inc
